Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4% – What’s Next?

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) traded down 4% on Monday . The stock traded as low as $11.30 and last traded at $11.61. 19,728 shares were traded during trading, a decline of 35% from the average session volume of 30,376 shares. The stock had previously closed at $12.10.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Greenwich LifeSciences Stock Performance

The firm has a market cap of $153.93 million, a P/E ratio of -14.64 and a beta of 1.69. The company’s 50 day moving average is $12.43 and its 200 day moving average is $13.21.

Insider Buying and Selling at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were bought at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the transaction, the chief executive officer now directly owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have purchased 9,500 shares of company stock worth $115,549. Insiders own 51.67% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GLSI. Garden State Investment Advisory Services LLC bought a new position in Greenwich LifeSciences in the 3rd quarter valued at about $253,000. State Street Corp raised its position in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after buying an additional 3,005 shares during the last quarter. Barclays PLC increased its stake in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after purchasing an additional 4,465 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.